- Home
- FIGS vs CLDX Comparison
FIGS vs CLDX Comparison
Compare FIGS & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FIGS | CLDX |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | FIGS | CLDX |
|---|---|---|
| Price | $14.40 | $28.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $13.42 | ★ $44.50 |
| AVG Volume (30 Days) | ★ 4.5M | 857.8K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 850.00 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $419,591,000.00 | $12,743,000.00 |
| Revenue This Year | $9.96 | $97.61 |
| Revenue Next Year | $10.12 | $252.01 |
| P/E Ratio | $75.76 | ★ N/A |
| Revenue Growth | 59.47 | ★ 87.78 |
| 52 Week Low | $3.57 | $14.40 |
| 52 Week High | $17.48 | $31.85 |
Technical Indicators
Market Signals| Indicator | FIGS | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 53.50 | 51.12 |
| Support Level | $10.76 | $24.70 |
| Resistance Level | $17.48 | $30.90 |
| Average True Range (ATR) | 0.91 | 1.22 |
| MACD | -0.23 | -0.14 |
| Stochastic Oscillator | 10.06 | 1.88 |
Price Performance
Historical ComparisonAbout FIGS FIGS Inc.
FIGS Inc is a healthcare apparel company. The Company designs and sells scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear and other apparel. The Company generates maximum revenue from United States. Sales are generated through the Company's digital platforms.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.